NICE has recommended obinutuzumab with mycophenolate for severe lupus nephritis after trials showed higher renal response and fewer flares.

ITI-5000 utilizes nucleic acid vaccine constructs engineered to preferentially deliver tumor-associated antigens (TAAs) to the MHC II compartment via LAMP-1, potentially enhancing antigen presentation ...

Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.

ADMA shares rose 13.8% over three months as demand for Asceniv surged, driving higher 2026 revenues and EBITDA targets amid ...

In 2026, the spotlight will be on a handful of therapeutic strategies that could change cancer care for patients by offering ...

Company to Initiate First-in-Human Phase 1 Clinical Trial in Q2 2026ROCKVILLE, Md.--(BUSINESS WIRE)--#Clinicaltrials--Immunomic Therapeutics, Inc. (“ITI”), a privately held clinical-stage ...

Patients with Waldenström Non-Hodgkin lymphoma in the U.S. achieved durable complete responses of up to 15 months using a chemotherapy-free CD19 CAR-NK (chimeric antigen receptor natural killer) cell ...

CM Stalin says he is ‘facing a crisis’ his predecessors didn't witness; criticises Governor Ravi for not reading speech in ...

The panel discussion, “Innovations in Breast Cancer Treatment,” examined the challenge of maintaining or increasing access to care as breast cancer treatment becomes more stratified through biomarker ...

Deadly and silent at first, the Nipah virus spreads rapidly with high mortality. Here's what experts want you to know.

Agenus Inc. , a leader in immuno-oncology innovation, today announced the expansion of its global Medical Affairs infrastructure and early-access support capabilities in response to increasing ...

Vaxcyte Doses First Participants in Phase 3 Study Evaluating Concomitant Administration of VAX-31 and Seasonal Influenza ...